热门资讯> 正文
Apogee Therapeutics Begins Dosing Volunteers in Phase 1 Atopic Dermatitis Trial
2024-08-19 20:43
08:43 AM EDT, 08/19/2024 (MT Newswires) -- Apogee Therapeutics (APGE) said Monday it has dosed the first participants for the phase 1 trial of APG990, the company's investigative subcutaneous treatment for atopic dermatitis.
Apogee said it expects interim data from the trial in 2025.
Shares of the company were down 2.1% in recent Monday premarket activity.
Price: 44.29, Change: -0.96, Percent Change: -2.12
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
